Cargando…

Molecular Mechanisms of Drug Resistance in Glioblastoma

Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, is highly resistant to conventional radiation and chemotherapy, and is not amenable to effective surgical resection. The present review summarizes recent advances in our understanding of the molecular mechanisms of thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Dymova, Maya A., Kuligina, Elena V., Richter, Vladimir A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232134/
https://www.ncbi.nlm.nih.gov/pubmed/34203727
http://dx.doi.org/10.3390/ijms22126385
_version_ 1783713570897264640
author Dymova, Maya A.
Kuligina, Elena V.
Richter, Vladimir A.
author_facet Dymova, Maya A.
Kuligina, Elena V.
Richter, Vladimir A.
author_sort Dymova, Maya A.
collection PubMed
description Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, is highly resistant to conventional radiation and chemotherapy, and is not amenable to effective surgical resection. The present review summarizes recent advances in our understanding of the molecular mechanisms of therapeutic resistance of GBM to already known drugs, the molecular characteristics of glioblastoma cells, and the barriers in the brain that underlie drug resistance. We also discuss the progress that has been made in the development of new targeted drugs for glioblastoma, as well as advances in drug delivery across the blood–brain barrier (BBB) and blood–brain tumor barrier (BBTB).
format Online
Article
Text
id pubmed-8232134
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82321342021-06-26 Molecular Mechanisms of Drug Resistance in Glioblastoma Dymova, Maya A. Kuligina, Elena V. Richter, Vladimir A. Int J Mol Sci Review Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, is highly resistant to conventional radiation and chemotherapy, and is not amenable to effective surgical resection. The present review summarizes recent advances in our understanding of the molecular mechanisms of therapeutic resistance of GBM to already known drugs, the molecular characteristics of glioblastoma cells, and the barriers in the brain that underlie drug resistance. We also discuss the progress that has been made in the development of new targeted drugs for glioblastoma, as well as advances in drug delivery across the blood–brain barrier (BBB) and blood–brain tumor barrier (BBTB). MDPI 2021-06-15 /pmc/articles/PMC8232134/ /pubmed/34203727 http://dx.doi.org/10.3390/ijms22126385 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dymova, Maya A.
Kuligina, Elena V.
Richter, Vladimir A.
Molecular Mechanisms of Drug Resistance in Glioblastoma
title Molecular Mechanisms of Drug Resistance in Glioblastoma
title_full Molecular Mechanisms of Drug Resistance in Glioblastoma
title_fullStr Molecular Mechanisms of Drug Resistance in Glioblastoma
title_full_unstemmed Molecular Mechanisms of Drug Resistance in Glioblastoma
title_short Molecular Mechanisms of Drug Resistance in Glioblastoma
title_sort molecular mechanisms of drug resistance in glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232134/
https://www.ncbi.nlm.nih.gov/pubmed/34203727
http://dx.doi.org/10.3390/ijms22126385
work_keys_str_mv AT dymovamayaa molecularmechanismsofdrugresistanceinglioblastoma
AT kuliginaelenav molecularmechanismsofdrugresistanceinglioblastoma
AT richtervladimira molecularmechanismsofdrugresistanceinglioblastoma